# Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)

> **NCT04996758** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 40 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- Recurrent or Metastatic Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Toripalimab and Anlotinib

## Key facts

- **NCT ID:** NCT04996758
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-30
- **Primary completion:** 2023-09-30
- **Final completion:** 2024-12-01
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996758, "Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04996758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*